AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03106844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
Study NCT03447899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Description: Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
Study NCT02705014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone
Description: A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
Study NCT05664347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal teach to goal education
Description: Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
Study NCT05664347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video based teach to goal education
Description: Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
Study NCT03515551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCnyeso
Description: Weekly IV infusions of IMCnyeso
Study NCT01037049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
Study NCT03965468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
Study NCT03965468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
Study NCT03965468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
Study NCT03965468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: SBRT of all oligo-metastatic lesions
Study NCT03965468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection - definitive local treatment.
Description: Surgical resection of primary tumour for patients with single station, non-bulky tumours.
Study NCT02099292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and DexaBEAM
Description: combination treatment
Study NCT02994199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active video gaming
Description: Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
Study NCT02607865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily
Study NCT02607865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Oral administration once-daily
Study NCT02607865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral administration once-daily
Study NCT02607865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral administration once-daily
Study NCT03227692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona Knee System
Description: Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
Study NCT03227692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona Knee System
Description: Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
Study NCT03227692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
Study NCT03227692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
Study NCT03227692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAssist Knee
Description: Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
Study NCT01196091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Study NCT01196091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo every 2 weeks
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
Study NCT01196091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo every 4 weeks
Description: Administered via subcutaneous injection for 52 weeks.
Study NCT01196091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Study NCT01196091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study NCT02221570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
Study NCT02355665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Spray
Description: Nicotine Spray
Study NCT02355665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match nicotine spray
Study NCT03501381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
Study NCT03501381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Study NCT03501381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Study NCT02968966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy regime
Description: Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
Study NCT04121052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.
Study NCT03965468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy - definitive local treatment.
Description: Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
Study NCT03965468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
Study NCT02322489 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham microcurrent therapy
Description: Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
Study NCT03323086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) with Technology Extender
Description: One, 45-60 minute BI, followed by three months of access to technology extenders
Study NCT03323086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brochure
Description: Brochures provided one time
Study NCT06187051 — intervention group
Intervention type: DEVICE
Intervention: FEVAR
Description: Relining the EVAR with FEVAR
Study NCT06187051 — intervention group
Intervention type: DEVICE
Intervention: Explantation
Description: open surgery to explant the previous EVAR
Study NCT03681873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extremely Low Dose CT
Description: Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
Study NCT01021839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grafts placement
Description: Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
Study NCT00242710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogen
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study NCT00242710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CE 0.45 mg/MPA 1.5mg
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study NCT00242710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study NCT06094686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: epicardial adipose tissue thickness
Description: EATT measured via transthoracic echocardiography
Study NCT00718991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectranetics Turbo elite™ excimer laser catheter
Description: The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
Study NCT04062240 — intervention group
Intervention type: DEVICE
Intervention: BIS sensor
Description: BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
Study NCT01057394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopically guided PVI Ablation
Description: Endoscopically Guided Ablation using the EAS-AC
Study NCT01057394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF PVI Ablation
Description: Radiofrequency ablation
Study NCT05414669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet 300 mg
Description: Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
Study NCT05414669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Placebo was given orally for a total of 3 days, beginning a day before ESWL.
Study NCT00126763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal Matrix Patch ZR-02-01
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
Study NCT00362440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Study NCT00362440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone or metformin
Study NCT00362440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone or metformin
Study NCT00362440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05312099 — intervention group
Intervention type: OTHER
Intervention: Case control
Description: Case control study
Study NCT03083470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
Study NCT03083470 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SOR007 Ointment Vehicle
Description: SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
Study NCT00264511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
Study NCT00327210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training
Study NCT03279146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir exalidex (TXL)
Description: Oral formulations
Study NCT03279146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir exalidex (TXL)
Description: Oral formulations
Study NCT00256204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 1mg once daily
Study NCT00256204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 2mg once daily
Study NCT00256204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03236649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
Study NCT03236649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Tosylate Tablets
Description: 400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
Study NCT03309293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples
Study NCT03309293 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: blood samples
Study NCT01430689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B
Description: Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained
Study NCT01430689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
Description: Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained
Study NCT02027350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD Leycom/Millar Instruments conductance catheter
Description: Conductance catheter-Pressure volume relationship
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised citric acid in serial dilutions
Description: Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised citric acid in serial dilutions
Description: Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised ATP solution in serial dilutions
Description: ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT02039999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised ATP solution in serial dilutions
Description: ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study NCT01830829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jalyn
Description: study drug
Study NCT01830829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03754842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (twice daily)
Description: Matching placebo
Study NCT03754842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)
Description: Elysium Basis TM, Elysium Health, Inc., NY, USA